Harnessing the immune system for the treatment of melanoma: current status and future prospects

Andrea W. Guennoun, Heba A. Sidahmed, Cristina Maccalli, Barbara Seliger, Francesco M. Marincola, Davide Bedognetti

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

ABSTRACT: When malignant melanoma is diagnosed early, surgical resection is the intervention of choice and is often curative, but many patients present with unresectable disease at later stages. Due to its complex etiology paired with well-documented chemoresistance and high metastatic potential, patients with advanced melanoma had a poor prognosis, and the treatment of this disease remained unsatisfactory for many years. Recently, targeted therapy, immune checkpoint inhibition, or combinatory approaches have revolutionized the therapeutic options of melanoma allowing considerable improvement in disease control and survival. In this review we will summarize these novel therapeutic strategies with particular focus on combinatory immunotherapies and further discuss recent data derived from immunogenomic studies and potential options to improve the therapeutic efficacy of immune modulatory approaches.

Original languageEnglish
Pages (from-to)879-893
Number of pages15
JournalExpert Review of Clinical Immunology
Volume12
Issue number8
DOIs
Publication statusPublished - 2 Aug 2016

Fingerprint

Immune System
Melanoma
Therapeutics
Immunotherapy
Survival

Keywords

  • abscopal effect
  • combination therapy
  • CTLA-4 inhibitors
  • immune checkpoint blockade
  • immunotherapy
  • Malignant melanoma
  • PD-1 inhibitor
  • PD-L1 inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Harnessing the immune system for the treatment of melanoma : current status and future prospects. / Guennoun, Andrea W.; Sidahmed, Heba A.; Maccalli, Cristina; Seliger, Barbara; Marincola, Francesco M.; Bedognetti, Davide.

In: Expert Review of Clinical Immunology, Vol. 12, No. 8, 02.08.2016, p. 879-893.

Research output: Contribution to journalReview article

@article{21789a09bda24684bfb7904f2660a0f2,
title = "Harnessing the immune system for the treatment of melanoma: current status and future prospects",
abstract = "ABSTRACT: When malignant melanoma is diagnosed early, surgical resection is the intervention of choice and is often curative, but many patients present with unresectable disease at later stages. Due to its complex etiology paired with well-documented chemoresistance and high metastatic potential, patients with advanced melanoma had a poor prognosis, and the treatment of this disease remained unsatisfactory for many years. Recently, targeted therapy, immune checkpoint inhibition, or combinatory approaches have revolutionized the therapeutic options of melanoma allowing considerable improvement in disease control and survival. In this review we will summarize these novel therapeutic strategies with particular focus on combinatory immunotherapies and further discuss recent data derived from immunogenomic studies and potential options to improve the therapeutic efficacy of immune modulatory approaches.",
keywords = "abscopal effect, combination therapy, CTLA-4 inhibitors, immune checkpoint blockade, immunotherapy, Malignant melanoma, PD-1 inhibitor, PD-L1 inhibitors",
author = "Guennoun, {Andrea W.} and Sidahmed, {Heba A.} and Cristina Maccalli and Barbara Seliger and Marincola, {Francesco M.} and Davide Bedognetti",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/1744666X.2016.1176529",
language = "English",
volume = "12",
pages = "879--893",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Harnessing the immune system for the treatment of melanoma

T2 - current status and future prospects

AU - Guennoun, Andrea W.

AU - Sidahmed, Heba A.

AU - Maccalli, Cristina

AU - Seliger, Barbara

AU - Marincola, Francesco M.

AU - Bedognetti, Davide

PY - 2016/8/2

Y1 - 2016/8/2

N2 - ABSTRACT: When malignant melanoma is diagnosed early, surgical resection is the intervention of choice and is often curative, but many patients present with unresectable disease at later stages. Due to its complex etiology paired with well-documented chemoresistance and high metastatic potential, patients with advanced melanoma had a poor prognosis, and the treatment of this disease remained unsatisfactory for many years. Recently, targeted therapy, immune checkpoint inhibition, or combinatory approaches have revolutionized the therapeutic options of melanoma allowing considerable improvement in disease control and survival. In this review we will summarize these novel therapeutic strategies with particular focus on combinatory immunotherapies and further discuss recent data derived from immunogenomic studies and potential options to improve the therapeutic efficacy of immune modulatory approaches.

AB - ABSTRACT: When malignant melanoma is diagnosed early, surgical resection is the intervention of choice and is often curative, but many patients present with unresectable disease at later stages. Due to its complex etiology paired with well-documented chemoresistance and high metastatic potential, patients with advanced melanoma had a poor prognosis, and the treatment of this disease remained unsatisfactory for many years. Recently, targeted therapy, immune checkpoint inhibition, or combinatory approaches have revolutionized the therapeutic options of melanoma allowing considerable improvement in disease control and survival. In this review we will summarize these novel therapeutic strategies with particular focus on combinatory immunotherapies and further discuss recent data derived from immunogenomic studies and potential options to improve the therapeutic efficacy of immune modulatory approaches.

KW - abscopal effect

KW - combination therapy

KW - CTLA-4 inhibitors

KW - immune checkpoint blockade

KW - immunotherapy

KW - Malignant melanoma

KW - PD-1 inhibitor

KW - PD-L1 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84965081763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965081763&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2016.1176529

DO - 10.1080/1744666X.2016.1176529

M3 - Review article

C2 - 27070898

AN - SCOPUS:84965081763

VL - 12

SP - 879

EP - 893

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 8

ER -